Soleus Capital Discloses 9.9% Passive Stake in CalciMedica (CALC)

TL;DR

**Soleus Capital just bought 9.9% of CalciMedica, signaling a big institutional bet on the biotech.**

AI Summary

Soleus Capital Master Fund, L.P., a hedge fund, along with its affiliates Soleus Capital Group, LLC, Soleus Capital, LLC, and Guy Levy, reported a significant passive stake in CalciMedica, Inc. (NASDAQ: CALC) as of January 23, 2024. This filing indicates that Soleus Capital now beneficially owns 1,700,000 shares of CalciMedica's Common Stock, representing 9.9% of the company's outstanding shares. This matters to investors because a large institutional investor taking a substantial position can signal confidence in the company's future prospects, potentially attracting more investor interest and influencing stock price.

Why It Matters

A major institutional investor like Soleus Capital taking a nearly 10% stake suggests they see value in CalciMedica, which could be a positive signal for current and prospective shareholders.

Risk Assessment

Risk Level: low — This filing indicates a passive investment, meaning Soleus Capital is not seeking to control or influence management, which generally poses lower risk than activist stakes.

Analyst Insight

A smart investor would view this as a potential vote of confidence from a sophisticated investor and might consider further research into CalciMedica's fundamentals and pipeline, especially given the passive nature of the stake.

Key Numbers

• 1,700,000 — Shares Beneficially Owned (The total number of CalciMedica shares Soleus Capital now owns.)
• 9.9% — Percentage of Class (The percentage of CalciMedica's Common Stock owned by Soleus Capital.)
• $0.0001 — Par Value per Share (The nominal value of CalciMedica's Common Stock.)
• January 23, 2024 — Date of Event (The date that triggered the requirement for this filing.)

Key Players & Entities

• Soleus Capital Master Fund, L.P. (company) — reporting person and beneficial owner of shares
• CalciMedica, Inc. (company) — subject company whose shares were acquired
• Guy Levy (person) — group member associated with Soleus Capital
• Soleus Capital Group, LLC (company) — group member associated with Soleus Capital
• Soleus Capital, LLC (company) — group member associated with Soleus Capital

Forward-Looking Statements

• CalciMedica's stock price will see increased trading volume in the short term due to the disclosure of Soleus Capital's significant stake. (CalciMedica, Inc.) — medium confidence, target: 2024-02-23
• Other institutional investors may initiate or increase their positions in CalciMedica, following Soleus Capital's lead. (CalciMedica, Inc.) — low confidence, target: 2024-07-26

FAQ

Key Financial Figures

• $0.0001 — ame of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securiti

Filing Documents

• ea192128-13gsoleus_calci.htm (SC 13G) — 106KB
• 0001213900-24-006981.txt ( ) — 108KB

From the Filing

SC 13G 1 ea192128-13gsoleus_calci.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CalciMedica, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 38942Q202 (CUSIP Number) January 23, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 38942Q202 1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Soleus Capital Master Fund, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) ( b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5 SOLE VOTING POWER 0 6 SHARED VOTING POWER 783,904 (1)(2) 7 SOLE DISPOSITIVE POWER 0 8 SHARED DISPOSITIVE POWER 783,904 (1)(2) 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 783,904 (1)(2) 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 7.4% (3) 12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) FI FOOTNOTES (1) The shares of common stock reported in this row are held by Soleus Capital Master Fund, L.P. (“Master Fund”). Soleus Capital, LLC (“Soleus Capital”) is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. Soleus Capital Group, LLC (“SCG”) is the sole managing member of Soleus Capital. Mr. Guy Levy is the sole managing member of SCG. Each of SCG, Soleus Capital and Mr. Guy Levy disclaims beneficial ownership of these securities held by Master Fund and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or for any other purpose, except to the extent of their respective pecuniary interests therein. (2) Includes presently exercisable warrants to purchase up to 391,952 shares of the common stock of the Issuer (“Common Stock”). (3) This percentage is calculated based upon 10,257,077 shares of Common Stock outstanding as of the close of business on January 23, 2024, after giving effect to the initial closing of the transaction contemplated by the Securities Purchase Agreement dated as of January 19, 2024 among the Issuer and the purchasers identified on the signature pages thereto (the “Financing”). 2 CUSIP No. 38942Q202 1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Soleus Capital, LLC 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) ( b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5 SOLE VOTING POWER 0 6 SHARED VOTING POWER 783,904 (1)(2) 7 SOLE DISPOSITIVE POWER 0 8 SHARED DISPOSITIVE POWER 783,904 (1)(2) 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 783,904 (1)(2) 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 7.4% (3) 12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO FOOTNOTES (1) The shares of common stock reported in this row are held by Master Fund. Soleus Capital is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. SCG is the sole managing member of Soleus Capital. Mr. Guy Levy is the sole managing member of SCG. Each of SCG, Soleus Capital and Mr. Guy Levy disclaims beneficial ownership of these securities held by Master Fund and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interests therein. (2) Includes presently exer

View Full Filing

View this SC 13G filing on SEC EDGAR